[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"opioid-use-disorder-severe\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:opioid-use-disorder-severe":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,50,77,104,127],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100643571","buprenorphine-implementation-at-syringe-service-programs-to-reduce-overdoses-100643571",false,"NCT07631598","Buprenorphine Implementation at Syringe Service Programs to Reduce Overdoses","Buprenorphine Implementation at Syringe Services Programs To Reduce Overdoses: A Type 1 Hybrid Effectiveness-Implementation Trial","BISTRO","Inclusion Criteria:\n\n1. ≥ 18 years old;\n2. Meet DSM-5 criteria for moderate or severe OUD;\n3. Interest in receiving buprenorphine treatment;\n4. Speaks English or Spanish;\n5. Currently an SSP client at the time of enrollment;\n6. Ability to provide informed consent.\n\nExclusion Criteria:\n\n1. Current use of prescribed opioid agonist treatment, as assessed by self-report, at the time of enrollment;\n2. Unstable mental health or medical condition that requires an immediate clinical evaluation or higher level of care;\n3. Allergy to buprenorphine;\n4. Currently detained in jail, prison, residential substance use treatment facility, or other overnight facility as required by court of law. or have pending legal action that could prevent participation on study activities.",true,"ALL","18 Years",{"count":21,"type":22},512,"ESTIMATED","INTERVENTIONAL",[25],"NA","This study is testing whether offering buprenorphine treatment directly at syringe service programs (SSPs) helps more people start and stay in treatment for opioid use disorder (OUD) than referring them to community buprenorphine treatment providers. Buprenorphine is a medication that helps reduce opioid cravings and withdrawal symptoms.\n\nThe study compares two ways of connecting people to treatment:\n\nReferral to a community treatment provider (usual care before the new program begins).\n\nOnsite, low-threshold buprenorphine treatment at the SSP, which allows participants to start medication quickly and without having to establish care at another provider.\n\nParticipants will be adults who have opioid use disorder and are SSP clients. Each SSP will begin offering the new onsite buprenorphine program at different times during the study. Researchers will collect information before and after the new program begins to see how it affects treatment engagement and health outcomes.\n\nThe study will also examine how easy or difficult it is for SSPs to start and run the new program, how acceptable it is to staff and participants, and whether it is cost-effective.\n\nThe overall goal is to find better ways to expand access to life-saving opioid treatment in community-based settings.",[28,29,30],"Opioid Use Disorder","Opioid Use Disorder, Severe","Opioid Use Disorder, Moderate",[32,33,34,35,36],"Buprenorphine","Overdose Prevention","Low-Threshold Treatment","Community-Based Treatment","Medication for Opioid Use Disorder","RECRUITING","2026-08-20",{"date":40,"type":41},"2026-08-21","ACTUAL",{"date":43,"type":41},"2026-08-17",{"date":45,"type":22},"2028-06",{"name":47,"class":48},"Montefiore Medical Center","OTHER",8,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":23,"phases":60,"briefSummary":61,"conditions":62,"keywords":63,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":76},"100652943","trtme-improving-outpatient-initiation-of-medication-for-opioid-use-disorder-following-hospitalization-100652943","NCT07780097","TRTME: Improving Outpatient Initiation of Medication for Opioid Use Disorder Following Hospitalization","A Pilot Randomized Controlled Trial to Improve Outpatient Initiation of Medication for Opioid Use Disorder (MOUD) Following Hospitalization: The TRTME (Tailored Overdose Risk Feedback, Testimonials for MOUD Treatment, and Education on MOUD and Opioid Overdose) Trial","TRTME","Inclusion Criteria:\n\n1. 18 years of age or older;\n2. A good candidate for methadone or buprenorphine treatment according to a member of the UCMC Addiction Consult Team\n\nExclusion Criteria:\n\n1. Have a current planned discharge to a nursing facility\n2. be currently in jail, prison, or any inpatient overnight facility as required by court of law or have pending legal action with high probability of incarceration or court-mandated inpatient treatment\n3. Unable to demonstrate adequate understanding of study procedures during the consent process",{"count":59,"type":22},30,[25],"The primary objective of this study is to evaluate the ability of TRTME to increase initiation of MOUD outpatient treatment and MOUD knowledge in hospitalized patients with OUD deemed to be good candidates for MOUD by the UCMC Addiction Consult Team (ACT). The secondary objective is to evaluate the ability of TRTME to decrease stigma and increase drug self-efficacy.",[28,30,29],[64,28,65,66,67],"opioid","MOUD","buprenorphine","methadone","2026-08-18",{"date":40,"type":41},{"date":71,"type":22},"2026-08-12",{"date":73,"type":22},"2027-02-28",{"name":75,"class":48},"T. John Winhusen, PhD",1,{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":23,"phases":87,"briefSummary":89,"conditions":90,"keywords":91,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":103},"100566130","phase-2-evaluation-of-tirzepatide-as-an-adjunct-to-buprenorphine-for-the-treatment-of-opioid-use-disorder-100566130","NCT06651177","Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder","NIDA CTN-0152: Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder: A Pragmatic, Multi-site, Double-blind, Randomized, Placebo-controlled Trial (TAB)","TAB","Inclusion Criteria:\n\n1. Must be ≥18 years of age;\n2. Must have moderate to severe OUD;\n3. Must, at the time of randomization, be newly initiated on BUP (i.e., within 7 to 80 days) during the current treatment episode, be taking ≥ 8 mg\u002Fday of generic buprenorphine-naloxone film\u002Ftablets (or the equivalent for other buprenorphine products), have documentation of receiving BUP, including dose and the start date of the current treatment episode, from their BUP provider, and, for participants prescribed transmucosal BUP, have at least one UDS positive for buprenorphine\u002Fnorbuprenorphine;\n4. Must be willing to be randomized to tirzepatide or placebo and to comply with study procedures, including weekly visits for 6 months;\n5. Must be able to understand the study, and having understood, provide written informed consent in English;\n6. Must not be breastfeeding; if of child bearing potential, must test negative on the study-administered pregnancy test(s), and if of childbearing potential and engaging \u002Fplanning to engage in sexual intercourse must agree to effective contraception for the duration of the trial through 30 days after the trial; effective contraception is defined as using: a) birth control injection, an intrauterine device, or implant; or b) two birth control methods - for example birth control pills with a barrier method (e.g., condoms, etc.).\n\n   * If ever of childbearing potential, a participant is considered to not be of childbearing potential for the study if they are:\n\n     1. infertile due to surgical sterilization (hysterectomy, bilateral oophorectomy, tubal implants, or tubal ligation), congenital anomaly such as Mullerian agenesis; are\n     2. post-menopausal defined as ≥ 55 years old not on hormone therapy, who has had at least 12 months of spontaneous amenorrhea;\n     3. ≥ 55 years old with a diagnosis of menopause prior to starting hormone replacement therapy; or\n     4. ≥ 40 years old with an intact uterus, not on hormone therapy, who has cessation of menses for at least 1 year without an alternative medical cause, AND a follicle-stimulating hormone ≥ 40 mIU\u002FmL; participants in this category must test negative on the study-administered pregnancy test(s).\n\nExclusion Criteria:\n\n1. have a history of type 1 or type 2 diabetes mellitus (other than pregnancy-related diabetes);\n2. have a BMI \\\u003C23.0 kg\u002Fm²;\n3. have any of the following cardiovascular conditions within 90 days prior to signing consent: acute myocardial infarction, cerebrovascular accident (stroke), unstable angina, or hospitalization due to congestive heart failure (CHF);\n4. have a known history of chronic or acute pancreatitis, gallbladder disease, gastroparesis, gastric emptying abnormality, gastroesophageal reflux disease, or other severe gastrointestinal disease;\n5. have a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2);\n6. have previously taken tirzepatide, have taken any GLP-1 analogue within the 6 months before consent, or have a known history of prior hypersensitivity reaction to any GLP-1 analogue;\n7. have renal impairment defined as an estimated glomerular filtration rate (eGFR) value of \\\u003C 15 mL\u002Fmin\u002F1.73 m2 or requiring dialysis;\n8. have a current, or within the 30 days prior to signing consent, use of, or plan to start during the course of the trial:\n\n   1. medications with glucose lowering properties: GLP-1 analogs, sulfonylurea, insulin, metformin, thiazolidinediones, dipeptidyl peptidase-4 (DPP-IV) inhibitors, sodium-glucose cotransporter-2 (SGLT-2) inhibitors;\n   2. systemic steroids including prednisone, hydrocortisone, dexamethasone;\n9. have a history of suicide attempts in the prior year or significant active suicidal ideation as assessed by a qualified study clinician;\n10. have a psychiatric or medical condition that, in the judgment of the site medical clinician (BMC or UMC), would make study participation unsafe or which would make treatment compliance difficult;\n11. have current status as a prisoner OR be currently in jail, prison, or any inpatient overnight facility as required by court of law or have pending legal action or other situation (e.g., unstable living arrangements) that, in the judgement of the site investigator, could prevent participation in the study or in any study activities.",{"count":86,"type":22},310,[88],"PHASE2","The primary objective of this research study is to evaluate the effect of tirzepatide, relative to placebo, as an adjunct to BUP on retention, substance use, and sleep outcomes in individuals with OUD.",[28,30,29],[92,64,93,66,94],"tirzepatide","opioid use disorder","GLP-1","2026-08-06",{"date":97,"type":41},"2026-08-11",{"date":99,"type":41},"2026-01-29",{"date":101,"type":22},"2027-10-31",{"name":75,"class":48},9,{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":108,"acronym":4,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":18,"minAge":110,"maxAge":111,"enrollmentInfo":112,"targetDuration":4,"studyType":23,"phases":114,"briefSummary":115,"conditions":116,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":76},"100649445","applying-low-intensity-focused-ultrasound-in-treating-severe-substance-use-disorder-tolerability-and-effectiveness-100649445","NCT07734623","Applying Low-Intensity Focused Ultrasound in Treating Severe Substance Use Disorder: Tolerability and Effectiveness","Inclusion Criteria:\n\n* Meets the DSM-5 criteria for opioid use disorder or amphetamine use disorder, with a severity level of severe, and does not currently meet the criteria for in sustained remission;\n* Within 7 days prior to the screening assessment, the participant must have been receiving a stable dose of medication treatment, such as methadone, buprenorphine\u002Fnaloxone, or naltrexone;\n* Within 7 days prior to the screening assessment, the participant must have abstained from illicit substances and alcohol, and must have a negative urine drug test;\n* The bilateral nucleus accumbens must be clearly identifiable on magnetic resonance imaging (MRI), such that they are sufficient for treatment targeting and for indirect measurement from other anatomical structures;\n* The participant must be able to communicate effectively and express their feelings and experiences during the study procedures;\n* The participant must be willing to comply with the study requirements, including adherence to prescribed medications and cooperation with study visits and assessments.\n\n(The participant must have the capacity to make independent medical decisions, as determined by the clinical team.)\n\nExclusion Criteria:\n\n* Presence of neurological disorders or major psychiatric disorders, such as acute-phase schizophrenia spectrum disorder, acute-phase bipolar disorder, acute-phase major depressive disorder, severe cognitive impairment, or recent suicidal ideation or plan;\n* Antisocial personality disorder;\n* Occurrence of major physical health problems within 6 months prior to the trial, including: Cardiovascular or hemodynamic abnormalities, such as heart failure, arrhythmia, tachycardia or bradycardia (\\>100 bpm or \\\u003C60 bpm), abnormal systolic blood pressure (\\>180 mmHg or \\\u003C90 mmHg), or abnormal diastolic blood pressure (\\>180 mmHg); Platelet or coagulation abnormalities (INR \\> 1.5) or current use of medications that may cause anticoagulation, such as warfarin or Avastin; Renal dysfunction (eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m²) or ongoing hemodialysis; Severe infection; Immunocompromised status; History of intracranial hemorrhage, intracranial aneurysm, cerebrovascular events within the past 6 months, or brain tumor; Neurological diseases, such as stroke, epilepsy, Parkinson's disease, dementia, or related disorders; Any other physical illness that, based on clinical evaluation, may pose a significant risk to physical function or life during treatment.\n* Participants who, upon evaluation, are deemed unsuitable for MR-guided focused ultrasound treatment, including those with a low skull density ratio (\\\u003C0.4), intracranial implants, or energy-absorbing structures or sensitive tissues along the ultrasound beam path that cannot be avoided (such as prior ventriculoperitoneal shunt sites, surgical metal clips, significant calcifications, extensive scarring, or any rigid implants). During the pre-treatment evaluation, a head CT scan will be performed to determine whether the skull density ratio is suitable for focused ultrasound treatment. Based on prior theoretical evidence, an excessively low skull density ratio may reduce the efficiency of MR-guided focused ultrasound and increase the risk of adverse effects, and therefore such participants are considered unsuitable for focused ultrasound treatment.\n* Structural abnormality of either side of the nucleus accumbens;\n* Contraindications to MRI, such as claustrophobia, allergy to MRI contrast agents, or the presence of metallic implants incompatible with MRI;\n* Contraindications to PET imaging, such as allergy to radiopharmaceutical contrast agents;\n* Inability to comply with trial-related instructions, lack of legal\u002Fbehavioral capacity, or lack of motivation to receive treatment;\n* Pregnancy or breastfeeding;\n* Scalp atrophy or poor wound healing of the scalp;\n* Any other condition that, in the physician's judgment, makes the participant unsuitable for enrollment in the clinical trial.","20 Years","50 Years",{"count":113,"type":22},60,[25],"The goal of this clinical trial is to investigate the safety and efficacy of applying low-intensity focused ultrasound targeting the nucleus accumbens in individuals with opioid or amphetamine use disorders. The main questions it aims to answer is:\n\n\\- Low-intensity focused ultrasound targeting the nucleus accumbens demonstrates sufficient safety and predictable therapeutic efficacy in individuals with opioid or amphetamine use disorders.\n\nParticipants will:\n\n* Received Low-intensity focused ultrasound neuromodulation once\n* Visit the clinic for checkups and asessment at 1 week, 1 month, 3 months, 6 months, 9 months, 1 year, 1.5 years, and 2 years after received Low-intensity focused ultrasound neuromodulation.",[29,117],"Amphetamine Use Disorder","2026-07-30",{"date":120,"type":41},"2026-07-31",{"date":122,"type":41},"2025-01-01",{"date":124,"type":22},"2030-12-31",{"name":126,"class":48},"National Taiwan University Hospital",{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":4,"eligibilityCriteria":133,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":134,"targetDuration":4,"studyType":23,"phases":136,"briefSummary":137,"conditions":138,"keywords":4,"overallStatus":139,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":149},"100627635","family-focused-study-to-support-medication-for-opioid-use-disorder-100627635","NCT07451197","Family-Focused Study to Support Medication for Opioid Use Disorder","Family-focused Digital Intervention for MOUD Initiation and Retention","Inclusion Criteria:\n\n* Be 18 years or older who meet the criteria for moderate or severe opioid use disorder (OUD) as determined by the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). Referred to as the \"Identified Patient\" or IP.\n* Be a parent, spouse or committed romantic partner, other family member, or friend, age 21 or older, of the individual with OUD. Referred to as \"Concerned Significant Other\" or CSO.\n* Able to communicate fluently in English.\n* Own a smartphone.\n\nExclusion Criteria:\n\n* IP must not have been on MOUD in the last 2 weeks.\n* CSO must not meet criteria for any severity of substance use disorder (SUD), except tobacco use.",{"count":135,"type":22},338,[25],"The purpose of this clinical trial is to develop and test whether a text- and web-based tool called FamilyCHESS - designed for individuals with opioid use disorder (OUD) and a concerned significant other (CSO) - can help the identified patient (IP) begin and stay on medication for opioid use disorder (MOUD).",[28,30,29],"NOT_YET_RECRUITING","2026-07-03",{"date":142,"type":41},"2026-07-07",{"date":144,"type":22},"2027-08-31",{"date":146,"type":22},"2031-08-31",{"name":148,"class":48},"University of Wisconsin, Madison",2]